Disclosed are an organic compound based on triazine and benzoxazole and an application thereof in an OLED device. The compound of the present application has a relatively high glass transition temperature and molecular thermal stability, is low in absorption and high in refractive index in the field of visible light, and is capable of effectively improving the light extraction efficiency of an OLED device when applied to a capping layer of the OLED device; with a deep HOMO energy level and high electronic mobility, the compound of the present application can be used as the hole blocking layer or the electron transport layer material, so that the recombination degree of the hole and the electron in the light-emitting layer can be improved, and thus the light-emitting efficiency of the OLED device can be enhanced and the service life of the OLED device can be prolonged.

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome. ##STR00001##

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

The present invention relates to polypiperidine compounds of polymeric type which are capable of conferring to the polymeric materials, particularly to polyolefins, a high stability against photodegradation and oxidative action of air, belong to the HALS category and have general formula (I): ##STR00001## wherein p is from 3 to 20; n is from 2 to 12; R and R.sub.1, which are the same or different, are selected in the group consisting of hydrogen, linear and branched C.sub.1-C.sub.12 alkyl groups, alkenyl groups having 3 to 8 carbon atoms and aralkyl groups having 7 to 19 carbon atoms; X and X.sub.1, which are the same or different, are selected in the group consisting oxygen and groups of formula (II) ##STR00002## wherein R.sub.2 is selected in the group consisting of hydrogen, linear and branched C.sub.1-C.sub.12 alkyl groups, cycloalkyl groups having 5 to 12 carbon atoms and aralkyl groups having 7 to 12 carbon atoms; A represents a —(CH.sub.2).sub.a— group wherein a is from 2 to 12, with the proviso that a is different from n; Z is selected in the group consisting of C.sub.1-C.sub.18 alkyl groups, groups of formula (III) ##STR00003## wherein n, X, X.sub.1, R and R.sub.1 are as above defined, and groups of formula (IV) ##STR00004## wherein R is as above defined; Y represents a substituent selected in the group consisting of the groups of general formula (V) ##STR00005## the groups O—R.sub.4 and S—R.sub.4, wherein R.sub.3 and R.sub.4, which may be the same or different, represent hydrogen, a linear and branched C.sub.1-C.sub.18 alkyl group, a cycloakyl group having 5 to 12 carbon atoms, an aralkyl group having 7 to 12 carbon atoms, an aryl group having 6 to 12 carbon atoms or may form, together with the nitrogen atom to which they are linked, a heterocycle containing 5 to 7 carbon atoms; and the piperidine group (VI) ##STR00006## wherein R and X are as above defined. The invention further relates to the processes for preparation of the compounds according to the invention.

The invention relates to compounds of structural formula I ##STR00001## wherein A, D, and E are independently N or C—R.sup.3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R.sup.3 or C—R.sup.3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R.sup.1 is selected from (C.sub.6 to C.sub.10) aryl, (C.sub.2 to C.sub.9) heteroaryl, and 5-indolyl, wherein each of the said (C.sub.6 to C.sub.10) aryl and (C.sub.2 to C.sub.9) heteroaryl is substituted with at least one R.sup.4a group, and wherein said (C.sub.2 to C.sub.9) heteroaryl is C-attached, and R.sup.2 is selected from the group consisting of ##STR00002##

The invention relates to compounds of structural formula I ##STR00001## wherein A, D, and E are independently N or C—R.sup.3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R.sup.3 or C—R.sup.3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R.sup.1 is selected from (C.sub.6 to C.sub.10) aryl, (C.sub.2 to C.sub.9) heteroaryl, and 5-indolyl, wherein each of the said (C.sub.6 to C.sub.10) aryl and (C.sub.2 to C.sub.9) heteroaryl is substituted with at least one R.sup.4a group, and wherein said (C.sub.2 to C.sub.9) heteroaryl is C-attached, and R.sup.2 is selected from the group consisting of ##STR00002##

The invention relates to compounds of structural formula I

##STR00001##

wherein A, D, and E are independently N or C—R.sup.3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R.sup.3 or C—R.sup.3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R.sup.1 is selected from (C.sub.6 to C.sub.10) aryl, (C.sub.2 to C.sub.9) heteroaryl, and 5-indolyl, wherein each of the said (C.sub.6 to C.sub.10) aryl and (C.sub.2 to C.sub.9) heteroaryl is substituted with at least one R.sup.4a group, and wherein said (C.sub.2 to C.sub.9) heteroaryl is C-attached, and R.sup.2 is selected from the group consisting of

##STR00002##

The invention relates to compounds of structural formula I

##STR00001##

wherein A, D, and E are independently N or C—R.sup.3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R.sup.3 or C—R.sup.3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R.sup.1 is selected from (C.sub.6 to C.sub.10) aryl, (C.sub.2 to C.sub.9) heteroaryl, and 5-indolyl, wherein each of the said (C.sub.6 to C.sub.10) aryl and (C.sub.2 to C.sub.9) heteroaryl is substituted with at least one R.sup.4a group, and wherein said (C.sub.2 to C.sub.9) heteroaryl is C-attached, and R.sup.2 is selected from the group consisting of

##STR00002##

A crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be prepared as a pharmaceutical composition.